The article critiques the U.S. Food and Drug Administration (FDA) for allegedly hindering scientific progress, particularly referencing the recent rejection of Moderna’s mRNA flu vaccine application for adults 50 and older. The FDA cited a lack of an “adequate and well-controlled” trial, despite the trial adhering to current regulations and being known to the agency for over a year. In contrast, regulatory bodies in the EU, Canada, and Australia are considering the vaccine based on the same trial data.
Amid public pressure, the FDA has agreed to review the vaccine, which is positive for seniors but does not resolve deeper issues within the agency, which is seen as undermining the U.S.’s position in biopharmaceutical innovation. The article highlights the importance of vaccines in addressing annual flu-related health risks, especially for older adults, and emphasizes that any delays in improving flu vaccines could lead to more severe health outcomes.
Furthermore, it notes the potential of mRNA technology in developing new treatments for various diseases, including cancer. However, the article warns that arbitrary decisions from the FDA may discourage investment and innovation in the pharmaceutical sector, ultimately harming patients and the development of future medicines. The FDA’s role in ensuring drug safety and fostering innovation is criticized as being compromised by erratic decision-making, which could have significant negative implications for public health and economic growth.
